跳至主要内容
临床试验/NCT06891170
NCT06891170已完成不适用

B Cell Responses in COVID-19: Generation of SARS-CoV-2 Neutralizing Human Monoclonal Antibodies to Efficiently Contrast Wild-type and Emerging Variants.

Fondazione IRCCS Policlinico San Matteo di Pavia1 个研究点 分布在 1 个国家目标入组 4 人开始时间: 2021年7月7日最近更新:

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
4
试验地点
1
主要终点
Optimization of the method to obtain human mAbs neutralizing COVID-19.

研究概览

简要总结

In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Cross Sectional

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age >18 at time of signing informed consent form
  • Signed informed consent form

排除标准

  • Ongoing drug abuse
  • Active or history of neoplastic malignancy
  • Active autoimmune disease ongoing treatment with immunosuppressive therapy
  • Ischemic heart disease
  • Evidence of positive HIV, HCV, HBV test
  • Failure to sign informed consent form

结局指标

主要结局

Optimization of the method to obtain human mAbs neutralizing COVID-19.

时间窗: From enrollment to 24 weeks

次要结局

未报告次要终点

研究者

发起方
Fondazione IRCCS Policlinico San Matteo di Pavia
申办方类型
Other
责任方
Principal Investigator
主要研究者

Barbara Oliviero

Principal Investigator

Fondazione IRCCS Policlinico San Matteo di Pavia

研究点 (1)

Loading locations...

相似试验